New study aims to predict organ damage in cancer patients on immunotherapy

NCT ID NCT07131007

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study enrolls 2000 cancer patients receiving immune checkpoint inhibitors. Researchers collect blood, urine, and stool samples before and after treatment to analyze genes, proteins, and other markers. The goal is to create a system that warns doctors early if a patient's organs are at risk of damage from immunotherapy. No new treatments are tested; this is purely observational.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a system that predicts organ damage early in cancer patients receiving immunotherapy, improving safety.

What could go wrong

This is an observational study, not a treatment trial. The system may not be accurate enough for real-world use, and results may take years to apply.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fourth Hospital of Hebei Medical University

    RECRUITING

    Shijiazhuang, Hebei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••